In this article, we identify the 13 Best Multibagger Stocks to invest in now.
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies. According to an article published by the CFA Institute citing the IMF, the United States remains resilient, with growth projected at 2.7%, while global GDP growth is at 3.3% in 2025.
In April, Reuters reported that the US and China paused their trade war. An agreement saw the U.S. cut its tariff rate from 145% to 30%, while China reduced its tariffs from 125% to 10%, for a period of 90 days. The stock markets climbed in reaction to these developments, reflecting investor optimism about easing trade tensions. Meanwhile, the fed rate remains between 4.25% and 4.50%, with no immediate plans for cuts, as mentioned by Fed Chair Jerome Powell.
Investors can capitalize on market volatility by investing in multibagger stocks. These are stocks that multiply in value several times over a short period, delivering returns far beyond the initial investment, building on their strong fundamentals, innovative business models, and significant expansion potential. Multibagger stocks present compelling growth prospects, particularly in volatile economic environments.
Our Methodology
We scanned the FinViz market screener to identify stocks that had a price of less than $20. We then filtered them for stocks that had a growth potential greater than 200% over the next twelve months, based on a consensus of analysts following these stocks. Our rankings are from lowest to highest based on their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13. Savara Inc. (NASDAQ:SVRA)
Upside Potential: 212.84%
Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company dedicated to addressing the unmet needs of patients suffering from rare respiratory diseases. Founded in 1995, Savara is a key player in this niche field through innovative therapeutic development and a commitment to delivering life-changing solutions to patients worldwide. The company focuses on diseases that have limited treatment options, ensuring its research has a significant impact on improving health outcomes.
The cornerstone of Savara Inc. (NASDAQ:SVRA) current pipeline is MOLBREEVI, a promising therapeutic designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, impeding gas exchange and leading to respiratory distress. MOLBREEVI is currently undergoing Phase 3 clinical trials and has already demonstrated notable improvements in gas exchange, as well as measurable clinical benefits for patients. Savara is actively pursuing regulatory approval through a rolling Biologics License Application (BLA) submission to the FDA, and it is preparing for a Marketing Authorization Application (MAA) to the European Medicines Agency. These efforts reflect Savara’s commitment to bringing MOLBREEVI to market as efficiently as possible.
Unlike many biopharmaceutical companies, Savara employs a unique business model that emphasizes outsourcing the majority of its clinical development and manufacturing activities to specialized vendors and consultants. This approach enables the company to operate in a capital-efficient manner, maximizing resources while maintaining the highest standards of quality and innovation. Additionally, Savara’s leadership team has extensive experience in navigating the complexities of drug development and commercialization, further strengthening its strategic position in the industry.
Financially, Savara Inc. (NASDAQ:SVRA) is in a strong position, with approximately $196 million in cash and short-term investments as of its latest financial report. This robust financial reserve ensures the company’s operations remain funded through Q2 2027, providing a solid foundation for advancing its pipeline and achieving its goals. Analysts have expressed optimism about Savara’s prospects, citing the company’s growing momentum, innovative pipeline, and prudent investment strategy as key drivers of its twelve-month average price target of $9.44, which reflects a substantial upside potential of 212.84%.
Hedge Fund Resource Center